Insider Trading April 16, 2026 08:31 PM

Phibro Animal Health Insider Sells $1.2M in Stock Amid Rally; Conversion Boosts Class A Shares

BFI Co., LLC and director Jack Bendheim executed sales April 14-16, 2026, while the company posted a stronger-than-expected fiscal Q2

By Priya Menon PAHC
Phibro Animal Health Insider Sells $1.2M in Stock Amid Rally; Conversion Boosts Class A Shares
PAHC

Director Jack Bendheim and a 10% holder, BFI Co., LLC, sold a combined $1,201,595 of Phibro Animal Health Corp. (PAHC) stock across multiple trades from April 14 to April 16, 2026. The disposals occurred as the share price traded near its 52-week high, and coincided with a reporting period in which the company reported fiscal Q2 results that outperformed analyst expectations.

Key Points

  • BFI Co., LLC and director Jack Bendheim sold PAHC shares totaling $1,201,595 between April 14 and April 16, 2026.
  • BFI Co., LLC executed sales at prices ranging from $54.5552 to $59.6924 and converted 100,000 Class B shares into Class A on April 16.
  • Phibro reported fiscal Q2 2026 EPS of $0.87 versus an expected $0.68, a 27.94% surprise, with revenue of $373.9 million beating the $355.24 million estimate by 5.25%.

Insider selling at Phibro Animal Health Corp. (NYSE: PAHC) totaled $1,201,595 across several transactions executed between April 14 and April 16, 2026, according to a company filing. The sellers identified were director Jack Bendheim and BFI Co., LLC, a reported 10% owner.

The stock has been trading near recent highs - $53.88 at the time of reporting and close to a 52-week peak of $60.08 - after a year that produced a 216% gain for the shares. Investment research from InvestingPro included with the filing notes that PAHC currently appears overvalued relative to its Fair Value and that 10 additional ProTips are available to subscribers.


Transaction details

  • April 14: 6,548 shares sold at an average price of $59.0338; 492 shares sold at an average price of $59.6924.
  • April 15: 2,623 shares sold at an average price of $56.2691; 3,618 shares sold at an average price of $57.2099; 799 shares sold at an average price of $58.1126.
  • April 16: 5,190 shares sold at an average price of $54.5552; 1,850 shares sold at an average price of $54.8759.

The aggregate proceeds from those sales totaled $1,201,595. All of the trades were attributed to BFI Co., LLC.

In addition to the sales, BFI Co., LLC converted 100,000 shares of Class B Common Stock into Class A Common Stock on April 16.

Post-transaction holdings

  • BFI Co., LLC now indirectly holds 117,000 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock.
  • Jack Bendheim directly holds 16,840 shares of Class A Common Stock.

Recent company performance

Phibro Animal Health reported fiscal second-quarter 2026 results that exceeded consensus expectations. The company posted earnings per share of $0.87, compared with the $0.68 analysts had forecast - a surprise of 27.94%. Quarterly revenue was $373.9 million, ahead of the $355.24 million that had been expected, representing a 5.25% beat.

The filing and accompanying commentary noted that the earnings beat has drawn attention from industry analysts focused on animal health, though the record did not specify any particular upgrades or downgrades from those firms.


Context and implications

The disclosed insider dispositions and the conversion of Class B shares to Class A provide a snapshot of recent ownership changes while the stock trades near annual highs and following a strong quarterly performance. InvestingPro’s valuation view, cited in the filing, characterizes the shares as appearing overvalued relative to Fair Value; additional proprietary tips are available to subscribers per the same analysis.

While the transactions and conversion alter the mix of share classes and confirm some liquidity taken by a significant holder, the filing does not include commentary on the motivations for the sales or any forward guidance tied to these ownership moves.

Risks

  • Insider selling by a 10% owner and a director may alter market perception of share demand - this could affect investor sentiment in the animal health and broader healthcare supply chain sectors.
  • InvestingPro’s analysis flags the stock as appearing overvalued relative to Fair Value, introducing valuation risk for equity investors in PAHC.
  • The filing does not disclose motives behind the sales or conversions, leaving uncertainty about whether transactions reflect personal liquidity needs or views on future company performance - this uncertainty impacts shareholders and market analysts following Phibro.

More from Insider Trading

Rakuten entities trim AST SpaceMobile stake in two-day $270 million sale Apr 16, 2026 Gloo Holdings CEO Makes Notable Insider Purchase Amid Mixed Financial Signals Apr 16, 2026 Gloo Holdings Director Patrick P. Gelsinger Acquires $264,634 of Class A Shares Apr 16, 2026 HeartBeam Director Richard Ferrari Purchases $50,000 of BEAT Stock Amid Recent Financing Apr 16, 2026 HeartBeam President Acquires $10,000 in Stock as Company Completes $10M Offering and Draws New Coverage Apr 16, 2026